ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST

Read more here:
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1...

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST

Go here to read the rest:
Inside information: Orion upgrades full-year outlook for 2024

MINNEAPOLIS, July 01, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced it has filed its Form 10-Q for the quarter ended March, 31, 2024 and in doing so has regained compliance with SEC reporting requirements.

Excerpt from:
Foxo Technologies, Inc., Regains Compliance with SEC Reporting Requirements

SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that Rocky Mountain Cancer Centers (RMCC), part of the US Oncology Network and Sarah Cannon Research Institute (SCRI); Astera Cancer Care (ACC), a multi-specialty community oncology practice and part of the OneOncology network; and Norton Cancer Institute, are open for enrollment in the pivotal Phase 2 ALPHA3 trial.

See the original post here:
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene...

LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA.

Read the rest here:
GRI Bio to Present at the 8th Annual IPF Summit

SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024.

See the original post here:
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Ricky Williams, former Heisman Trophy winner, renowned cannabis advocate, and founder of the cannabis brand Highsman, has expressed his strong support for the NCAA's recent decision to remove cannabinoids from its list of banned substances. This groundbreaking move marks a significant shift in the acceptance of cannabis in sports and aligns with the growing recognition of its potential benefits.

Continued here:
Ricky Williams Applauds NCAA’s Decision to Remove Cannabinoids from Banned Substances List, Emphasizes Need for Education on Cannabis

SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium being held June 30 to July 5, 2024 in Salamanca, Spain.

Here is the original post:
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research...

The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11%

The rest is here:
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development...

PALO ALTO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provided certain preliminary unaudited financial results for the month ended June 30, 2024 and quarter ended June 30, 2024.

See the rest here:
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024